Myasthenia gravis disease-modifying therapy
Evidence-based management of myasthenia gravis (MG) uses (1) symptomatic neuromuscular transmission support, (2) early disease control with immunotherapy for generalized MG, (3) thymic-directed therapy when indicated, and (4) escalation to short-term rescue and longer-term refractory options when response is inadequate. [1]
Medication selection algorithm
Symptomatic therapy
- Acetylcholinesterase inhibitors (including pyridostigmine) are used for symptomatic improvement in MG weakness. [1]
- Rapid discontinuation of acetylcholinesterase inhibitors is avoided during crisis or impending crisis because worsening weakness may occur. [1]
First-line immunotherapy for generalized MG
- Glucocorticoids (including prednisone) are used as first-line steroid immunotherapy for generalized MG to achieve disease control. [1]
- Steroid-sparing conventional immunosuppressants are added when longer-term steroid reduction is needed (including azathioprine, mycophenolate mofetil, cyclosporine, and tacrolimus). [1]
Thymic-directed therapy
- Thymectomy is recommended for patients with generalized MG when thymoma is present and should be considered in appropriate non-thymomatous generalized MG. [1]
- Evidence supporting thymectomy plus prednisone over prednisone alone comes from the randomized MGTX trial in non-thymomatous generalized AChR-antibody–positive MG. [2]
Refractory and/or treatment-failure escalation
- Short-term rescue is performed with IVIG or plasma exchange for severe exacerbations or myasthenic crisis. [1]
- FcRn inhibitors are used in generalized MG after inadequate response to conventional therapy and are selected by antibody status and availability. [3]
- Complement inhibition is used in AChR-antibody–positive refractory generalized MG after inadequate response to conventional therapy. [4]
- Rituximab is used as a non–first-line biologic option in selected refractory MG phenotypes, including AChR- and MuSK-associated disease that fails conventional immunotherapy. [1]
Key evidence supporting first-line and escalation therapies
Thymectomy plus prednisone vs prednisone alone
- In MGTX, thymectomy plus standardized prednisone reduced the time-weighted average Quantitative Myasthenia Gravis (QMG) score over 3 years compared with prednisone alone. [2]
- A post hoc analysis of MGTX outcomes reported a 19.2% (95% CI 5.9% to 32.6%) absolute difference in thymectomy vs prednisone-only groups for prednisone withdrawal at a defined endpoint measure. [5]
Complement inhibition for refractory generalized AChR+ MG
- Eculizumab in the phase 3 REGAIN trial evaluated safety and efficacy in anti–AChR–positive refractory generalized MG after inadequate control with prior therapies. [4]
- Complement inhibition is indicated for AChR-antibody–positive generalized MG in the US with meningococcal vaccination and prophylaxis requirements. [6]
FcRn inhibition for generalized MG
- Efgartigimod is FDA approved for generalized MG in adults who test positive for anti–AChR antibody. [3]
- Efgartigimod prescribing information supports use for generalized MG in adults (including multiple formulations). [7]
- FDA approval frameworks for FcRn inhibitors include antibody-defined generalized MG populations and short-interval re-treatment courses. [7]
Monotherapy vs combination therapy
Conventional immunotherapy
- Steroid therapy is used as a main disease-control strategy for generalized MG. [1]
- Steroid-sparing immunosuppressants are commonly combined with glucocorticoids to facilitate steroid minimization when long-term control is required. [1]
Thymectomy integration
- Thymectomy is used in combination with a standardized prednisone protocol in appropriate patients, based on randomized trial evidence. [2]
Refractory escalation and rescue
- IVIG or plasma exchange are used as rescue strategies rather than durable immunotherapy. [1]
- Complement inhibition and FcRn inhibition are used as ongoing immunomodulatory therapies for refractory generalized MG rather than immediate crisis rescue. [4] [3]
Important clarifications and nuances
Antibody-defined targeting
- AChR-antibody positivity is required for complement inhibition strategies using eculizumab in refractory generalized MG. [4]
- FcRn inhibition with efgartigimod is FDA-approved for generalized MG in adults testing positive for anti–AChR antibody. [3]
Thymoma-associated MG
- Thymoma-associated generalized MG is managed with thymectomy when feasible, because thymic pathology-directed treatment is part of standard management pathways. [1]
Treatment initiation thresholds
When to initiate systemic immunotherapy
- Generalized MG is treated with systemic immunotherapy for disease control beyond symptomatic therapy. [1]
When to initiate rescue therapy
- Severe exacerbations or myasthenic crisis are treated with rapid-acting rescue therapy using IVIG or plasma exchange. [1]
When to escalate to refractory biologics
- Escalation to complement inhibition or FcRn inhibition is performed after inadequate control with prior immunosuppressive strategies in generalized MG. [4] [3]
Common pitfalls to avoid
- Inadequate differentiation between ocular MG and generalized MG leads to delayed initiation of systemic immunotherapy when generalized disease control is required. [1]
- Failure to use steroid-sparing strategies in patients requiring prolonged glucocorticoids increases cumulative steroid toxicity risk. [1]
- Complement inhibitor use without required meningococcal vaccination and prophylaxis increases risk of meningococcal infection. [6]
Target goals of therapy
- Durable clinical improvement with transition toward minimal manifestation status and reduction of dependence on high-dose glucocorticoids is an accepted treatment goal in generalized MG strategies that include thymectomy and immunosuppression. [5] [2]
- Short-term disease control of symptoms and activities of daily living is targeted during rescue and biologic induction phases. [1]